Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGDR2 | Q9Y5Y4 | 2/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | BRD9 | Q9H8M2 | 1/20 | 0.32 |
| ▸ | SCN9A | Q15858 | 4/20 | 0.32 |
| ▸ | GCGR | P47871 | 1/20 | 0.31 |
| ▸ | RORC | P51449 | 1/20 | 0.31 |
| ▸ | KCNK3 | O14649 | 1/20 | 0.31 |
| ▸ | MAOA | P21397 | 2/20 | 0.30 |
| ▸ | MMP2 | P08253 | 1/20 | 0.30 |
| ▸ | MMP3 | P08254 | 1/20 | 0.30 |
| ▸ | MMP9 | P14780 | 1/20 | 0.30 |
| ▸ | MMP8 | P22894 | 1/20 | 0.30 |
| ▸ | MMP13 | P45452 | 1/20 | 0.30 |
| ▸ | MMP14 | P50281 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14717976 | 0.90 | SMN1; SMN2 (0.33) | PTGDR2SMN1; SMN2SCN9AGCGRRORC | |
| SCHEMBL1660442 | 0.90 | SMN1; SMN2 (0.33) | PTGDR2SMN1; SMN2BRD9SCN9AGCGR | |
| SCHEMBL14730955 | 0.90 | PTGDR2 (0.33) | PTGDR2SMN1; SMN2BRD9SCN9AGCGR | |
| SCHEMBL6904451 | 0.89 | SMN1; SMN2 (0.36) | PTGDR2SMN1; SMN2SCN9AGCGRRORC | |
| SCHEMBL14717940 | 0.89 | PTGDR2 (0.33) | PTGDR2SMN1; SMN2BRD9SCN9AGCGR | |
| SCHEMBL14718229 | 0.88 | POLB (0.38) | PTGDR2SMN1; SMN2SCN9AKCNK3 | |
| SCHEMBL14718104 | 0.86 | PTGDR2 (0.36) | PTGDR2SMN1; SMN2SCN9AGCGRRORC | |
| SCHEMBL14717156 | 0.82 | SCN9A (0.37) | SCN9A | |
| SCHEMBL14717715 | 0.82 | PTGS2 (0.34) | BRD9SCN9AMAOAMMP2MMP3 | |
| SCHEMBL14718164 | 0.80 | LMNA (0.35) | SMN1; SMN2SCN9AGCGRRORC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8871796-B2 | Diaryl ether derivatives as notch sparing gamma secretase inhibitors | MERCK SHARP & DOHME CORP. (US) | 2014-10-28 | — | — | US | claimed |
| US-20130053386-A1 | DIARYL ETHER DERIVATIVES AS NOTCH SPARING GAMMA SECRETASE INHIBITORS | MERCK SHARP & DOHME LLC | 2013-02-28 | — | — | US | claimed |
| US-8871796-B2 | Diaryl ether derivatives as notch sparing gamma secretase inhibitors | MERCK SHARP & DOHME CORP. (US) | 2014-10-28 | — | — | US | disclosed |
| US-8871796-B2 | Diaryl ether derivatives as notch sparing gamma secretase inhibitors | MERCK SHARP & DOHME CORP. (US) | 2014-10-28 | — | — | US | disclosed |
| US-8871796-B2 | Diaryl ether derivatives as notch sparing gamma secretase inhibitors | MERCK SHARP & DOHME CORP. (US) | 2014-10-28 | — | — | US | disclosed |
| US-20130053386-A1 | DIARYL ETHER DERIVATIVES AS NOTCH SPARING GAMMA SECRETASE INHIBITORS | MERCK SHARP & DOHME LLC | 2013-02-28 | — | — | US | disclosed |
| US-20130053386-A1 | DIARYL ETHER DERIVATIVES AS NOTCH SPARING GAMMA SECRETASE INHIBITORS | MERCK SHARP & DOHME LLC | 2013-02-28 | — | — | US | disclosed |
| US-20130053386-A1 | DIARYL ETHER DERIVATIVES AS NOTCH SPARING GAMMA SECRETASE INHIBITORS | MERCK SHARP & DOHME LLC | 2013-02-28 | — | — | US | disclosed |
| EP-2488031-A1 | DIARYL ETHER DERIVATIVES AS NOTCH SPARING GAMMA SECRETASE INHIBITORS | Merck Sharp & Dohme Corp. (US) | 2012-08-22 | — | — | EP | disclosed |
| WO-2011046774-A1 | DIARYL ETHER DERIVATIVES AS NOTCH SPARING GAMMA SECRETASE INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2011-04-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130053386-A1 | DIARYL ETHER DERIVATIVES AS NOTCH SPARING GAMMA SECRETASE INHIBITORS | BACE1, BACE2, GSAP | PTGDR2 1751/4885SMN1; SMN2 3441/4885BRD9 897/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.